The team is joined by GuestKats Mirko Brüß, Rosie Burbidge, Nedim Malovic, Frantzeska Papadopolou, Mathilde Pavis, and Eibhlin Vardy
InternKats: Rose Hughes, Ieva Giedrimaite, and Cecilia Sbrolli
SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Hayleigh Bosher (Book Review Editor), and Tian Lu (Asia Correspondent).

Wednesday, 22 December 2004


Canada: a haven for generic drugs?

Medical News Today reports that Canada is proposing to amend its patent law in order to optimize the balance between encouraging continued innovation in new drugs and promoting timely generic competition. Under the proposal pharmaceutical companies will not be able to extend the period of data exclusivity that they are granted in a way that is incompatible with the original purpose of such protection. This should enable generics to come to the market more easily. However, for genuinely innovative drugs, the data exclusivity period will be extended from 6 years to 8 years, with an extra 6 months for drugs which have been the subject of clinical trials on children.

The IPKat welcomes this subtle approach, which directs its measures specifically to the problems identified, rather than a “one size fits all” approach.

More on generic drugs in Canada here, here and here
Canada-related Monty Python sketch here

1 comment:

Anonymous said...

very interesting discussion on transport canada I have a related blog here transport canada

Subscribe to the IPKat's posts by email here

Just pop your email address into the box and click 'Subscribe':